AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04966897 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GlycosBio Nutritional Supplement + PERT placebo
Description: The lipid (fat) in the GlycosBio Nutritional Supplement (GBNS) was provided in the form of a re-structured lipid monoacylglyceride (MAG) produced by the study sponsor. MAGs are readily absorbed by enterocytes without the need of digestion by pancreatic lipases. The MAG oil is produced enzymatically from almond oil. The product also contains essential amino acids, carbohydrates as simple sugars and fat-soluble vitamins and minerals. The GBNS to be administered in a volume sufficient to supply 0.5 g of MAG per kg of body weight
Study NCT04966897 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard Nutritional Supplement + PERT
Description: A 5.9% fat triacylglycerol-based commercially available nutritional supplement (Boost Plus®, Nestlé Health Science, Bridgewater, NJ) in a volume sufficient to supply 0.5 g of TAG per kg of body weight over the same time period and PERT capsules (24,000 iu/capsule) at a dose of 2,500 iu of lipase activity per gram of fat ingested.
Study NCT01297647 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: urodynamic examination
Description: Standard urodynamic investigation according to the ICS standard, Good urodynamic practice.Following insertion of 8 F transurethral catheter, retrograde filling of the bladder (20 mL/min) with body warm saline.~Current recording of pabd. , pves and pdet., subsequently pressure flow study. Additionally imaging with fluoroscopy to detect possible vesico ureteral renal reflux.
Study NCT00772577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren Hydrochlorothiazide
Description: Aliskiren HCTZ 150/12.5 mg: 1 week; Aliskiren HCTZ 300/25 mg: 7 weeks
Study NCT00772577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril
Description: Ramipril 5mg: 1 week; Ramipril 10 mg: 7 weeks
Study NCT00831727 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expressive Writing
Description: Participants will write about their experienced trauma for 20 minutes on each of three consecutive days using techniques associated with expressive writing
Study NCT00831727 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Participants will write as factually as possible about an assigned trivial topic for 20 minutes on each of three consecutive days
Study NCT02477761 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrient preload
Description: Ingestion of a small mixed protein and lipid meal 30 minutes before glucose
Study NCT02318927 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: Deep Brain Stimulation (DBS) of Globus Pallidum plus Pedunculopontine Nucleus, including lead implant and battery placement. Magnetic Resonance Imaging and Computed Tomography (CT) scan will be obtained prior to implant. Measurement of number of Freezing of Gait (FoG) episodes during a FoG test at a lab. Other measures include freezing of gait questionnaire, gait and falls questionnaire, activities/balance confidence scale, Parkinson's disease quality of life questionnaire, Unified Parkinson's Disease Rating Scale physiology collection and sensor testing, adverse event recording, falls diaries, tracking use of assistive devices, gait and balance testing, and neuropsychological, neurosurgical, neurological, and physical exams.
Study NCT05074589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan liposome、5-Fluorouracil、Leucovorin
Description: Irinotecan liposome、5-Fluorouracil、Leucovorin
Study NCT05074589 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo、5-Fluorouracil、Leucovorin
Description: Placebo、5-Fluorouracil、Leucovorin
Study NCT01998321 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient specific instrument
Description: A special software with the ability to perform 3D planning including sizing, alignment, bone cutting, positioning of implants, simulation \& PSI designing and PSI production
Study NCT01998321 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional technique for TKA
Study NCT02153047 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spirometry
Description: Will be given a brief but structured smoking cessation advice (according to the standards of the Tobacco Study Group of the Catalan Society of Family Medicine) together with a detailed and structured 20-minutes visit with details of the spirometry data (values of respiratory capacity and volumes referring on the theoretical)
Study NCT01261481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: Tolvaptan 15 mg administered once orally as an intact tablet.
Study NCT01261481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: Tolvaptan 15 mg administered once via nasogastric tube.
Study NCT03341286 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TK3
Description: Tryptophan and thiamine as on oral supplement
Study NCT03341286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TK3
Description: Tryptophan and thiamine as on oral supplement
Study NCT04206189 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: carbohydrate group - carbohydrate (400ml)
Description: Randomly selected patients of the carbohydrate group are given oral carbohydrate (400ml) 2-3 hours before surgery. In contrast, patients in the control group are fasted water 2 hours before surgery according to the standard protocol.
Study NCT01030861 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teplizumab
Description: intravenous infusions
Study NCT01030861 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo infusion
Description: Placebo for Teplizumab
Study NCT01384695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorescein
Description: fluorescent contrast agent, Fluorescein 5ml
Study NCT03458884 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory interval training
Description: A structured cardiorespiratory interval training program on an ergometer cycle 3 days a week for 8 weeks.
Study NCT01384695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proflavine hemisulfate
Description: 3 ml of 0.01% proflavine (derived from dissolving 10mg proflavine hemisulfate USP in 100ml sterile water)
Study NCT05717881 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Propolis
Description: Propolis supplements were packaged in marine capsules and consisted of poplar propolis powder (propolis concentrate, carob powder, magnesium stearate and silicon dioxide), concentrated to 30% total polyphenols.~Each supplementation period lasted 3 months, with a 2-week wash-out period, to allow total excretion of polyphenols by the body and do not interfere with the new supplementation phase.~The subjects in this study were submitted to five visits, allowing the tracking of biological parameters (clinical examination, fasting blood samples, HGPO) during the study. During the supplementation phases, follow-up by telephone call was performed.
Study NCT05717881 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo powder capsules (maltodextrin, fatty acids, magnesium salts and silicon dioxide) are presented in the same packaging to have an identical appearance and taste. Patients in the propolis group were dosed with propolis to reach 6 mg total polyphenols/kg body weight, based on the results of a previous preclinical study in mice.~Each supplementation period lasted 3 months, with a 2-week wash-out period, to allow total excretion of polyphenols by the body and do not interfere with the new supplementation phase.~The subjects in this study were submitted to five visits, allowing the tracking of biological parameters (clinical examination, fasting blood samples, HGPO) during the study. During the supplementation phases, follow-up by telephone call was performed.
Study NCT00482313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PR OROS Methylphenidate
Description: PR OROS Methylphenidate given orally once daily for 5 weeks. The dosage was as follows: 36 mg per day from day 1-3, 54 mg per day from day 4-7 and 72 mg per day from day 8 until end of 5th week.
Study NCT00482313 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill
Study NCT03179618 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Anti-Platelet Drugs
Description: Including aspirin and clopidogrel, etc.
Study NCT03179618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Platelet Drugs
Description: Including aspirin and clopidogrel, etc.
Study NCT03179618 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lipid Regulating Drugs
Description: Mainly including statins
Study NCT03179618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipid Regulating Drugs
Description: Mainly including statins
Study NCT03179618 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Coronary Vasodilator
Description: Mainly including nitrates
Study NCT03179618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coronary Vasodilator
Description: Mainly including nitrates
Study NCT03179618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xuefu Zhuyu Decoction
Description: Mainly including Peach Kernel, Safflower, Angelica, Bupleurum etc.
Study NCT03189797 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tailored preventive program
Description: In the study group they were given a preventive program as homecare program including tooth brushing 2/day with a fluoride toothpaste( 5000 ppm F) following the instructions in addition to fluoride mouth rinse. For the clinical approach motivational engagement was done by discussing with patients how to improve oral health behavior including amount of sugar, fibrous food and junk food. This in addition to pits and fissures sealant, F- varnish 2 times /year. and application of fluoride varnish every 6 months and dietary intake interventions.
Study NCT00794261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of Pegfilgrastim
Description: Single subcutaneous administration of Pegfilgrastim (Neulasta® - Laboratory AMGEN) 6 mg at D5
Study NCT00794261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Injection of Filgrastim
Description: Daily subcutaneous administration of Filgrastim (Neupogen® - Laboratory AMGEN) 5 µg/kg/day from D5 until recovery from aplasia (PNN > 0.5 G/L)
Study NCT04434313 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delivery of iStride™ device gait treatment using telemedicine
Description: The gait device used in this study mimics the actions of the split-belt treadmill but can be used during overground walking and in one's own home, thus enabling long-term training. This device does not require any external power and is completely passive; all necessary forces are redirected from the natural forces present during walking. This research aims to adapt the delivery mechanism of treatment with the iStride™ device to include telemedicine. The telemedicine platform of reference in this study, the Moterum Digital Platform, is an integrated therapeutic platform which offers an activity library, real-time video conferencing, and outcomes tracking. Our primary study objective is to determine if telemedicine is a safe and feasible delivery method for treatment with the iStride ™ gait device.
Study NCT00132509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFIL
Description: Alteplase : 0.8mg/kg over 90 minutes
Study NCT00132509 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NINDS
Description: Alteplase : 0.9mg/kg over 60 minutes
Study NCT00171509 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine microemulsion
Study NCT04637984 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PREP2 algorithm
Description: A) PREP2. It combines clinical measures and neurological biomarkers in the initial days after stroke: 1) SAFE score (day 3), which is the sum of shoulder abduction and finger extension strength in the paretic upper limb using the Medical Research Council (MRC); 2) NIH Stroke Scale (day 3); 3) transcranial magnetic stimulation (day 3-7) to determine the presence of MEPs in the paretic arm. According with the aforementioned measures, 4 categories of upper limb recovery will be identified: EXCELLENT, GOOD, LIMITED and POOR.
Study NCT02892110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: 2 mg daily
Study NCT02892110 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 mg daily
Study NCT00249106 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADVAX
Study NCT00249106 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: ADVAX
Study NCT03360708 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00171509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine microemulsion
Study NCT03360708 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine
Description: Given ID
Study NCT03465410 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard dosage of Tacrolimus
Description: Immediate release Tacrolimus (Prograf/Adoport)
Study NCT03465410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bayesian Prediction Tacrolimus dosage
Description: Immediate release Tacrolimus (Prograf/Adoport)
Study NCT02570126 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varilrix HSA-free
Description: 2 doses will be administered, one at Day 0 and the other at Day 42
Study NCT02570126 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Varilrix™
Description: 2 doses will be administered, one at Day 0 and the other at Day 42
Study NCT03351972 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Klean Prep
Description: Participants randomised to use polyethylene glycol will follow either routine guidance of taking the bowel prep the night before their capsule endoscopy or receive guidance that they should split their dose between the night before and the morning of the procedure
Study NCT03351972 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clear liquids only
Description: Participants randomised to clear liquids only will receive guidance to only drink clear liquids before their procedure
Study NCT02045394 — intervention group
Intervention type: OTHER
Intervention: Chest X-ray
Study NCT04357522 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 15-Valent Pneumococcal Conjugate Vaccine
Description: 4/1 dose(s) according to age of subjects. Single intramuscular dose contains 0.5ml 15-Valent Pneumococcal Conjugate Vaccine.
Study NCT04357522 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 13-Valent Pneumococcal Conjugate Vaccine
Description: 4/1 dose(s) according to age of subjects. Single intramuscular dose contains 0.5ml 15-Valent Pneumococcal Conjugate Vaccine.
Study NCT00764010 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: No dietary counseling and omega-3 capsules
Description: Omega-3 2.4 g/day
Study NCT00764010 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 capsules and dietary counseling
Description: Omega-3 2.4 g/day and Mediterranean-like diet
Study NCT00764010 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary counseling, placebo capsules for omega-3
Description: Mediterranean-like diet
Study NCT03565159 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar 13
Description: Pneumococcal polysaccharide conjugate vaccine
Study NCT03565159 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9%
Description: Placebo
Study NCT01387516 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Intervention
Description: The MI session will be 60-90 minutes in length.The focus is on establishing rapport and building motivation. The counselor explores teen's reasons for entering treatment, prior treatment experience, previous attempts to change use, possible goals for treatment, substance effect expectancies, and perceptions of self-efficacy.A personalized feedback report outlines assessment results, highlights any problems or concerns related to cigarette use expressed by teen, and compares tobacco use levels with national norms for same age and gender peers.
Study NCT01387516 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Therapy
Description: The Relaxation Therapy intervention encompasses several techniques, including Progressive Muscle Relaxation and Visualization-Imagination, and meditation to reduce stress; which may lead to substance use.
Study NCT01387516 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: The Cognitive-Behavioral Therapy (CBT) Intervention focuses on the interrelationship between thoughts, feelings, and behaviors. It addresses specific deficits, such as improving problem solving skills and developing social supports, and behaviors such as substance abuse and smoking.
Study NCT01387516 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Help Programming
Description: The Self-Help Programming intervention combines elements of Nicotine anonymous (NicA) to provide someone who uses nicotine but wants a nicotine-free life, with a community of people that has also experienced nicotine addiction and strives to be nicotine free. It incorporate the 12 Steps and the NicA tools (i.e., meetings, phone list, literature, sponsorship, and service) to facilitate and maintain abstinence from nicotine.
Study NCT02954029 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ezClot (hemostasis pad)
Description: ezClot pad uses chitosan, a deacetylated complex carbohydrate derived from the naturally occurring substance chitin, to accelerate blood clotting.
Study NCT02954029 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BloodSTOP ix pad
Description: BloodSTOP® pad is an etherized and oxidized regenerated cellulose matrix that achieves hemostasis by activating the intrinsic coagulation pathway.
Study NCT02954029 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rotary compression device
Description: Rotary compression device consists of a plastic arch and a rotary screw to deliver local pressure by moving the silicone compression pad.
Study NCT02954029 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rotary compression device
Description: Rotary compression device consists of a plastic arch and a rotary screw to deliver local pressure by moving the silicone compression pad.
Study NCT00003140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Given orally
Study NCT00003140 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study NCT02999269 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MECTA Spectrum 5000Q Amplitude
Description: Current
Study NCT02999269 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MECTA Spectrum 5000Q Amplitude
Description: Current
Study NCT02045394 — intervention group
Intervention type: OTHER
Intervention: computed tomography of the chest
Study NCT02045394 — intervention group
Intervention type: PROCEDURE
Intervention: Bronchoscopy
Description: In patients with haemoptysis bronchoscopy will be performed with flexible bronchoscope. A systemic research of bleeding site and causes will be done. Microbiological or pathological sampling will be executed if clinically required. In selected patients, bronchoscopy might be performed with the rigid instrument or the flexible bronchoscope in intubated patients.
Study NCT01379872 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional Study
Description: This is a non-interventional study
Study NCT02610738 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Junior KICk-OFF education programme
Description: The Junior KICk-OFF course is an age appropriate eduction course which aims to improve the understanding and knowledge of children with type 1 diabetes. It has been designed with school teachers and educationalists to meet the learning needs of children aged 4-11yrs
Study NCT03128996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RIC regimen
Description: Days -60 to -21: hydroxyurea (30mg/kg/day po) >6hrs prior to 1st dose: alemtuzumab (3mg IV) Day -21: alemtuzumab (10mg IV or S/C) Day -20: alemtuzumab (15mg IV or S/C) (10mg if \< 10kg) Day -19: alemtuzumab (20mg IV or S/C) (10mg if \< 10kg) Days -8 to -4: fludarabine (30mg/m2/day IV) Day -4: thiotepa (8mg/kg IV) Day -3: melphalan (140mg/m2) Days -2 to -1: rest days/no therapy Day 0: bone marrow transplant
Study NCT03128996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GVHD prophylaxis regimen
Description: Day +3 to +4: cyclophosphamide (50mg/kg/day IV) Day +5: Start of tacrolimus \& Start of mycophenolate mofetil (MMF) Days +5, +14, +30, +60, +90: abatacept (IND) (10mg/kg/day IV) Days +120 to +390: abatacept (IND) monthly (5mg/kg/day IV)
Study NCT00569582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mifepristone
Description: Patients take mifepristone by mouth once a day. The dose is increased during scheduled timepoints during the study or until symptoms improve or the highest dosage allowed is reached. Dose escalation will be based upon weight. During clinic visits, blood pressure, glucose tolerance and blood chemistries are measured and EKG and urinalysis will be performed.